1. Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience
- Author
-
Nicola Ragni, Silvana Chiara, G.C Parodi, L. Merlini, Flavio Carnino, S. Mammoliti, G. Foglia, E Guercio, Mario Roberto Sertoli, R. Rosso, Pierfranco Conte, Franco Odicino, Milena Bruzzone, Cristina Oliva, G. Parodi, and L Iskra
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,Time Factors ,Cyclophosphamide ,medicine.medical_treatment ,Internal medicine ,Ovarian carcinoma ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Stage (cooking) ,Aged ,Neoplasm Staging ,Ovarian Neoplasms ,Cisplatin ,Chemotherapy ,business.industry ,Middle Aged ,Prognosis ,medicine.disease ,Regimen ,Chemotherapy, Adjuvant ,Toxicity ,Female ,business ,Ovarian cancer ,medicine.drug - Abstract
87 patients with high risk of recurrence FIGO stage I and II ovarian carcinoma were treated with adjuvant chemotherapy consisting of cisplatin 50 mg/m2 plus cyclophosphamide 600 mg/m2 on day 1 every 28 days for 6 courses. Toxicity and efficacy of the regimen was evaluated after a median follow-up of 45 months. Treatment-related toxicity was mild and reversible, consisting chiefly of acute WHO grade 2 myelosuppression (10% of patients) and controllable grade 3 emesis (55%). No late toxicity was observed. Actuarial 7-year survival and relapse-free survival (RFS) were 76% and 61%, respectively; a statistically significant difference in outcome was observed for undifferentiated grade tumour (G1 vs. G2 vs. G3: P less than 0.01) but not for FIGO stage disease (stage I vs. stage II). In our opinion, short-term chemotherapy including the most active single agent, i.e. cisplatin, appears a tolerable and effective treatment which deserves further evaluation in large randomised trials.
- Published
- 1991
- Full Text
- View/download PDF